Reading Time: 1 minute
The decline in GLP-1 revenues at Hims & Hers clearly indicates that the main reason cited by Novo Nordisk for the current weakness is not entirely valid. It is not primarily the increasing competition from generic products that has pressured the market – rather, the initial hype seems to have passed. An internal white paper from Hims puts it succinctly: while only about 25% of the patients cared for by Hims discontinue their therapy after six months, the average discontinuation rate in the industry is around 80%. Many consumers have tried...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
